Condition: Infertility · Obesity · Sponsor: Fundacion Dexeus
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
This description comes directly from the study's public registry record.
Nikolaos P Polyzos, MD, PhD · 0034932274700 · nikpol@dexeus.com
Ignacio Rodríguez, MSc · 0034932274700 · nacrod@dexeus.com
Always discuss trial participation with your own doctor first.
| Dexeus Mujer Sabadell | Sabadell, Barcelona, Spain | Not Yet Recruiting |
| Dexeus Mujer Sant Cugat | Sant Cugat del Vallès, Barcelona, Spain | Not Yet Recruiting |
| Dexeus Mujer Reus | Reus, Tarragona, Spain | Not Yet Recruiting |
| Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus | Barcelona, Spain | Recruiting |
| Dexeus Mujer Tarragona | Tarragona, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07242534